There are several phase 3 trials evaluating GLP-1s for indications, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy, and osteoarthritis of the knee (in patients with obesity)
This variability highlights why sourcing options, program eligibility, and clinician guidance are essential for practical affordability
Employers should keep in mind that indication-based coverage decisions (such as covering GLP-1 drugs for diabetes treatment but not for treatment of obesity or other conditions, such as addiction) can potentially raise concerns under the Americans with Disabilities Act (ADA), the ACA, HIPAAs nondiscrimination requirements, or the Mental Health Parity and Addiction Equity Act, among other laws
Partner link: PDP may earn a commission at no cost to you
To activate hepatic TR, mice were injected with MB07811 at a dose of 5 mg/kg/day
With these advancements, there is still a significant possibility to produce innovative treatments that increase the efficacy, safety, quality, and durability of weight reduction
